5-(2-Pyrazinyl)pyrimidin | 65610-37-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(2-Pyrazinyl)pyrimidin
• 英文别名: 5-pyrazin-2-yl-pyrimidine；2-Pyrimidin-5-ylpyrazine
• CAS: 65610-37-9
• 化学式: C₈H₆N₄
• 分子量: 158.162
• InChiKey: CJJMKQXMQWSGRT-UHFFFAOYSA-N

物化性质

• 熔点：
  128-129 °C(Solv: ligroine (8032-32-4))
• 沸点：
  323.6±32.0 °C(Predicted)
• 密度：
  1.239±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-甲基吡嗪 、 N,N’,N’’-次甲基三甲酰胺 、 甲酰胺 以6%的产率得到
  参考文献：
  名称：

  HIROTA T.; KOYAMA T.; BASHO C.; NANBA T.; SASAKI K.; YAMATO M., CHEM. AND PHARM. BULL., 1977, 25, NO 11, 3056-3060

  摘要：

  DOI：

文献信息

• MGLUR7 AGONIST COMPOUNDS FOR TREATING MGLUR7-REGULATED DISEASES, DISORDERS, OR CONDITIONS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20190345148A1

  公开（公告）日：2019-11-14

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof wherein Z, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy. The present invention further provides methods of treating at least one disease, disorder, or condition associated with the glutamatergic and GABAergic signalling pathways regulated in full or in part by metabotropic glutamate receptor 7 (mGluR7) by administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject. The compound may be a selective agonist of mGluR7, which modulates the release of at least one neurotransmitter in the subject.